Treating Inadequately Controlled Asthma: Exploring the Potential of Phenotype-Targeted Therapy - European Medical Journal


Treating Inadequately Controlled Asthma: Exploring the Potential of Phenotype-Targeted Therapy

| Download as | PDF
Mario Castro1
Ratko Djukanovic,2 Michael Wechsler3

Mario Castro has received research support from NIH, ALA, CDC, Amgen, Boston Scientific, Boehringer Ingelheim, Cephalon, Genentech, GSK, Invion, Johnson & Johnson, Kalobios, MedImmune, NextBio, Novartis, Sanofi Aventis, and Vectura. He is on the lecture bureau for Boehringer Ingelheim, Boston Scientific, Genentech, GSK, and Teva. He has acted as consultant for Boston Scientific, Galera, Genentech, GSK (DSMC), Holaira, MEDA, and Neostem. He holds stock in Sparo Labs. Ratko Djukanovic has acted as consultant for Teva, Novartis, Merck, Boehringer Ingelheim, and Synairgen. Michael Wechsler has provided consulting services to the following companies: Teva, GSK, Genentech, Boston Scientific, Novartis, Merck, AstraZeneca, and Boehringer Ingelheim.


Writing assistance was provided by Dr Tabasum Mughal, ApotheCom.


The publication of this article was funded by Teva Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.

EMJ Respir. ;3[2]:42-48.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Asthma is inadequately treated with the current standard of care. This session aimed to explore the potential of a phenotype-targeted approach to asthma management, which would allow a more tailored approach to treatment and result in better clinical outcomes for difficult-to-treat patients. Evidence was presented indicating that eosinophils play an important role in the pathogenesis of asthma. The importance of anti-interleukin (IL)-5 therapies, with the focus on therapies currently in development and their potential clinical benefit for the eosinophilic asthma phenotype, was also explored.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list